journal
MENU ▼
Read by QxMD icon Read
search

Journal of Ocular Pharmacology and Therapeutics

journal
https://www.readbyqxmd.com/read/28922088/semifluorinated-alkane-eye-drops-for-treatment-of-dry-eye-disease-due-to-meibomian-gland-disease
#1
Philipp Steven, Albert J Augustin, Gerd Geerling, Thomas Kaercher, Florian Kretz, Kathleen Kunert, Johannes Menzel-Severing, Norbert Schrage, Wolfgang Schrems, Sonja Krösser, Michael Beckert, Elisabeth M Messmer
PURPOSE: Meibomian gland disease is generally accepted as the leading cause for evaporative dry eye disease (DED). In a previous study, perfluorohexyloctane, a semifluorinated alkane, has been demonstrated to significantly increase tear film breakup time and to reduce corneal fluorescein staining in patients with evaporative DED, thereby vastly reducing dry eye-related symptoms. This study was set up to evaluate perfluorohexyloctane in a larger population of patients with Meibomian gland dysfunction...
September 18, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28910175/neurotrophic-keratopathy-therapeutic-approach-using-a-novel-matrix-regenerating-agent
#2
Marta Guerra, Sara Marques, João Quadrado Gil, Joana Campos, Paula Ramos, Andreia Martins Rosa, Maria João Quadrado, Joaquim Neto Murta
PURPOSE: To evaluate the efficacy and tolerance of a new matrix-regenerating agent (RGTA), Cacicol(®), a polymer that mimics heparan sulfates bound to extracellular matrix proteins, avoiding its proteolysis, to treat neurotrophic keratopathy (NK). METHODS: Uncontrolled prospective clinical study performed between January 2014 and May 2016. Twenty-five patients (25 eyes) with corneal neurotrophic ulcers, nonresponsive to at least 2 weeks of conservative therapy, were treated with Cacicol, instilled once/twice a week...
September 14, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28854348/changing-initial-glaucoma-medical-therapy-increases-healthcare-resource-utilization
#3
Matthew G J Trese, Andrew W Lewis, Taylor S Blachley, Joshua D Stein, Sayoko E Moroi
PURPOSE: To determine the frequency and economic impact of changing initial glaucoma therapy for patients with newly diagnosed open-angle glaucoma (OAG) or ocular hypertension (OHT). METHODS: This retrospective longitudinal cohort study identified individuals within a large managed care network in the United States, who were newly diagnosed with OAG or OHT from 2001 to 2012 and were prescribed either a topical beta blocker (BB) or a prostaglandin analog (PGA). Claims data were analyzed over the 12-month period following their index prescription to determine physician prescribing habits, healthcare resource utilization patterns, and sociodemographic factors which may have contributed to changing the initial treatment strategy...
August 30, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28846481/effectiveness-of-combined-tear-film-therapy-in-patients-with-evaporative-dry-eye-with-short-tear-film-breakup-time
#4
Yung Hui Kim, Yeon Soo Kang, Hyo Seok Lee, Won Choi, In Cheon You, Kyung Chul Yoon
PURPOSE: The aim of this study was to evaluate the effectiveness of combined tear film therapy targeted to aqueous, mucin, and lipid layers in patients with refractory evaporative dry eye (EDE) with short tear film breakup time (TBUT). METHODS: The patients who had EDE with short TBUT and severe symptoms refractory to artificial tears were treated with hyaluronic acid (HA) 0.15% and diquafosol tetrasodium (DQS) 3% (Group 1), HA and carbomer-based lipid-containing eyedrops (Liposic EDO Gel, LPO) (Group 2), or HA, DQS, and LPO (Group 3)...
August 28, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28836880/long-term-intravitreal-dexamethasone-treatment-in-eyes-with-pretreated-chronic-diabetic-macular-edema
#5
Souska Zandi, Théo Lereuil, Florentina Freiberg, Maximilian Pfau, Isabel B Pfister, Christin Gerhardt, Stephan Michels, Laurent Kodjikian, Justus G Garweg
PURPOSE: The aim of this study is to assess the effect of repeated injections of dexamethasone implants in patients with persistent diabetic macular edema (DME) despite prior therapies. METHODS: This retrospective interventional study involved 47 DME-afflicted eyes, which were administered ≥2 intravitreal injections of dexamethasone. Group 1 (34 eyes) received a dexamethasone monotherapy, whereas group 2 (13 eyes) received a combination therapy with intravitreal antivascular endothelial growth factor as needed...
August 24, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28829220/neovascular-age-related-macular-degeneration-disease-quiescence-with-visual-acuity-stability-in-a-subgroup-of-patients-following-prn-treatment
#6
Greg D Fliney, Leonid M Zukin, Curtis Hagedorn
PURPOSE: This study evaluates long-term visual acuity (VA) outcomes in patients with prolonged clinically quiescent neovascular age-related macular degeneration (AMD) after treatment with a pro re nata (PRN) regimen of anti-vascular endothelial growth factor agents (bevacizumab, ranibizumab, and/or aflibercept). METHODS: This retrospective study analyzes VA changes in 105 eyes from 72 patients with a period of AMD disease quiescence (determined by retinal examination) not requiring treatment for at least 180 days...
August 22, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28820649/targets-of-neuroprotection-in-glaucoma
#7
Shaoqing He, Dorota L Stankowska, Dorette Z Ellis, Raghu R Krishnamoorthy, Thomas Yorio
Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking...
August 18, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28820646/consequences-of-puberty-on-efficacy-of-intraocular-pressure-lowering-drugs-in-male-dutch-belted-rabbits
#8
Cassandra L Hays, Kingsley C Okafor, Shan Fan, Robin High, Dhirendra P Singh, Carol B Toris
PURPOSE: To investigate the changes in intraocular pressure (IOP), aqueous flow, and outflow facility, as well as efficacy of IOP-lowering drugs before and after sexual development in rabbits. METHODS: Male Dutch-belted rabbits were studied at night between the ages of 8 and 44 weeks. During these times, body weight, testicular volume, and serum testosterone were measured to monitor sexual maturity. Ocular measurements included anterior chamber depth, central corneal thickness, IOP, aqueous flow, and outflow facility...
August 18, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28813632/eyes-on-new-product-development
#9
Gary D Novack
No abstract text is available yet for this article.
August 16, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28813622/the-effect-of-posture-on-intraocular-pressure-and-systemic-hemodynamic-parameters-in-treated-and-untreated-patients-with-primary-open-angle-glaucoma
#10
Andreas Katsanos, Anna I Dastiridou, Luciano Quaranta, Eliana Rulli, Ivano Riva, Varvara Dimasi, Evangelia E Tsironi, Robert N Weinreb
PURPOSE: To assess intraocular pressure (IOP), systolic, diastolic, and mean arterial blood pressure (SBP, DBP, MAP) changes in the sitting, supine, and 20° head-down (Trendelenburg) position in treated (tPOAG) and untreated (uPOAG) primary open-angle glaucoma patients and healthy controls. METHODS: All participants underwent IOP and systemic BP measurements in the sitting, supine, and Trendelenburg positions during office hours. IOP and BP readings in the sitting, supine, and Trendelenburg positions were analyzed...
August 16, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28783422/the-role-of-nitric-oxide-in-the-intraocular-pressure-lowering-efficacy-of-latanoprostene-bunod-review-of-nonclinical-studies
#11
Megan E Cavet, Heleen H DeCory
Latanoprostene bunod (LBN) is a topical ophthalmic therapeutic for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT). LBN is composed of latanoprost acid (LA) linked to a nitric oxide (NO)-donating moiety and is the first NO-releasing prostaglandin analog to be submitted for marketing authorization in the United States. The role of latanoprost in increasing uveoscleral outflow of aqueous humor (AqH) is well established. Herein, we review findings from nonclinical studies, which evaluated the role of NO in the IOP-lowering efficacy of LBN...
August 7, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28771380/antioxidant-and-osmoprotecting-activity-of-taurine-in-dry-eye-models
#12
Claudio Bucolo, Annamaria Fidilio, Chiara Bianca Maria Platania, Federica Geraci, Francesca Lazzara, Filippo Drago
PURPOSE: To assess the protective effects of ophthalmic formulations based on taurine (TAU) and sodium hyaluronate (SH) in ocular surface. METHODS: Rabbit corneal epithelial cells [Statens Seruminstitut Rabbit Cornea (SIRC)] were subjected to oxidative stress (1 mM H2O2) and treated with the following formulations: 0.2% SH, 0.4% SH, 0.4% SH +0.5% TAU. Reactive oxygen species (ROS) were evaluated by commercial kit. Dry eye was induced by atropine sulfate and topical treatment was carried out with the following formulations: 0...
August 3, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28719234/the-in-vivo-effects-of-the-cb1-positive-allosteric-modulator-gat229-on-intraocular-pressure-in-ocular-normotensive-and-hypertensive-mice
#13
Elizabeth A Cairns, Anna-Maria Szczesniak, Alex J Straiker, Pushkar M Kulkarni, Roger G Pertwee, Ganesh A Thakur, William H Baldridge, Melanie E M Kelly
PURPOSE: Orthosteric cannabinoid receptor 1 (CB1) activation leads to decreases in intraocular pressure (IOP). However, use of orthosteric CB1 agonists chronically has several disadvantages, limiting their usefulness as clinically relevant drugs. Allosteric modulators interact with topographically distinct sites to orthosteric ligands and may be useful to circumvent some of these disadvantages. The purpose of this study was to investigate the effects of the novel CB1-positive allosteric modulator (PAM) GAT229 on IOP...
July 18, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28704121/evaluation-of-in-vitro-antiamoebic-activity-of-antimicrobial-agents-against-clinical-acanthamoeba-isolates
#14
Hidemasa Nakaminami, Kentaro Tanuma, Kiichi Enomoto, Yukihiko Yoshimura, Tomoyo Onuki, Shin Nihonyanagi, Yukihiro Hamada, Norihisa Noguchi
PURPOSE: The aim of this study was to elucidate in vitro antiamoebic activity of antimicrobial agents at short exposure times similar to those used for actual treatment against Acanthamoeba strains isolated from patients with keratitis. METHODS: The 5 clinical Acanthamoeba isolated in Japan were used in this study. Identification of genotypes for the Acanthamoeba isolates was performed using partial 18S ribosomal DNA (rDNA), including the ASA.S1 region sequences...
July 13, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28700254/diquafosol-delivery-from-silicone-hydrogel-contact-lenses-improved-effect-on-tear-secretion
#15
Carmen Dominguez-Godinez, Gonzalo Carracedo, Jesus Pintor
PURPOSE: The aim of this study was to evaluate the ability to uptake and to deliver diquafosol from commercial contact lenses (CLs) and its effect on tear secretion. METHODS: For both in vitro and in vivo experiments, two commercial silicone hydrogel (Si-Hy) CLs (comfilcon A and balafilcon A) were used. The CLs were soaked overnight for 12 h in diquafosol solution and control CLs were soaked in saline solution (NaCl 0.9%). The CLs were introduced into a new well container with 1 mL of saline solution, and aliquots of 100 μL were extracted at different times during a period of 6 h to measure the diquafosol release...
July 12, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28686538/differential-intraocular-pressure-measurements-by-tonometry-and-direct-cannulation-after-treatment-with-soluble-adenylyl-cyclase-inhibitors
#16
Jarel K Gandhi, Uttio Roy Chowdhury, Zahid Manzar, Jochen Buck, Lonny R Levin, Michael P Fautsch, Alan D Marmorstein
PURPOSE: To validate the increase in intraocular pressure (IOP) caused by soluble adenylyl cyclase (sAC) inhibitors and determine reasons behind variation in IOP measurements performed by tonometry. METHODS: C57BL/6J mice were administered DMSO solubilized sAC inhibitors (KH7 or LRE-1) by intraperitoneal injection. Two hours post-treatment, mice were anesthetized with avertin or ketamine/xylazine/acepromazine (KXA). IOP was measured by a rebound tonometer or direct cannulation of the anterior chamber...
July 7, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28650720/nonclinical-development-of-env905-difluprednate-ophthalmic-implant-for-the-treatment-of-inflammation-and-pain-associated-with-ocular-surgery
#17
Rozemarijn S Verhoeven, Andres Garcia, RiLee Robeson, Brian C Gilger, David Culp, Craig Struble, Lee Hamm, Tomas Navratil, Benjamin Yerxa
PURPOSE: Topical corticosteroids are widely used in the treatment of inflammation and pain after ocular surgery, but they possess several shortcomings, including frequent dosing and low patient adherence. We evaluated the efficacy and pharmacokinetics of ENV905 (difluprednate or DFBA) Ophthalmic Implant, a single-dose drug delivery system, compared with 0.05% Durezol. METHODS: PRINT(®) technology was used to fabricate ENV905 implants for either intracameral (IC) or subconjunctival (SCJ) delivery of extended-release DFBA...
June 26, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28777040/making-basic-science-studies-in-glaucoma-more-clinically-relevant-the-need-for-a-consensus
#18
Carol B Toris, Claire Gelfman, Andy Whitlock, William E Sponsel, Cheryl L Rowe-Rendleman
Glaucoma is a chronic, progressive, and debilitating optic neuropathy that causes retinal damage and visual defects. The pathophysiologic mechanisms of glaucoma remain ill-defined, and there is an indisputable need for contributions from basic science researchers in defining pathways for translational research. However, glaucoma researchers today face significant challenges due to the lack of a map of integrated pathways from bench to bedside and the lack of consensus statements to guide in choosing the right research questions, techniques, and model systems...
September 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28759302/evaluation-of-clinical-efficacy-and-safety-of-a-novel-cyclosporin-a-nanoemulsion-in-the-treatment-of-dry-eye-syndrome
#19
Hyun Seung Kim, Tae-Im Kim, Jin Hyoung Kim, Kyung Chul Yoon, Joon Young Hyon, Ko Un Shin, Chul Young Choi
PURPOSE: Topical administration of the anti-inflammatory agent cyclosporin A (CsA) is recommended for long-term management of dry eye syndrome (DES), yet standard ophthalmic CsA preparations have been reported to be unstable. In this trial, the efficacy and safety of Clacier™ (based on a phase 3 study developed by Huons Co. Ltd.), a novel 0.05% CsA nanoemulsion formulation, are compared with those of the conventional Restasis(®) emulsion. METHODS: Patients with moderate-to-severe DES were randomly assigned to receive topical 0...
September 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28753094/eyes-on-new-product-development
#20
Gary D Novack
No abstract text is available yet for this article.
September 2017: Journal of Ocular Pharmacology and Therapeutics
journal
journal
32321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"